



DOI: 10.32768/abc.2021811-3

Classification of the Clinical Presentation, Severity, and Response to Treatment in Idiopathic Granulomatous Mastitis

Ahmad kaviani^{*a,b,c}, Mahtab Vasigh^{a,c}

^a Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran

^b Department of Surgical Oncology, University of Montreal, Montreal, Canada

^c Breast Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran

Idiopathic granulomatous mastitis (IGM), also called idiopathic lobular mastitis, is a rare, benign inflammatory condition of the breast with currently unknown etiology. The cornerstone of the design of a clinical trial relies on the type and the severity of the clinical findings and the response to the treatment strategy applied. Without a standard classification, we may not expect to accomplish uniform investigations in different centres. According to the considerable experience of the authors and considering our previous publications, we suggest a classification in four grades according to the clinical manifestation (inflammatory, cutaneous, soft tissue, and systemic findings). Severity can predict the treatment response, so we suggest the therapeutic modalities be chosen based on this factor.

Idiopathic granulomatous mastitis (IGM), also called idiopathic lobular mastitis, is a rare, benign inflammatory condition of the breast with currently unknown etiology.¹ The course of the disease is sometimes chronic and devastating for the patients.² It mostly affects women of childbearing age with a history of pregnancy or lactation within the last five years of the onset of the disease.³⁻⁵ This is a rare condition in developed countries; however, it is more prevalent in developing countries. Recently there has been an increase in the number of studies in this regard. The reports mostly come from middle-east countries, including Iran and Turkey.⁴

Although an increase in the number of studies is evident, and it is a well-known clinical condition since 1972⁶, there is not yet a general consensus regarding the management of this disease.^{7,8} In the

literature, there is a disparity in clinical findings, diagnosis, management, and follow-up of the disease in different studies.

The cornerstone of the design of a clinical trial relies on the type and the severity of the clinical findings and the response to the treatment strategy applied. Without a standard classification, we may not expect to accomplish uniform investigations in different centres.

The clinical presentation of the disease contains a wide range of signs including inflammatory symptoms resembling infectious mastitis or inflammatory carcinoma depending on the severity and extent of the inflammation. On the other hand, some patients would refer to medical centres with breast mass and tissue thickening. This group of symptoms are mostly related to the collection with or without inflammation that may mimic breast cancer. Finally, in some situations, the breast complaints are a part of a systemic disease. The clinical manifestation of the disease is summarized in Table 1.

Three hundred seventy-four patients were analysed in our previous work.⁹ The severity of the disease in that study was categorized into three levels. Considering our previous publications⁹⁻¹⁴, we made some modifications to the classification system we used. We classify the severity of the disease in Table 2, based on the clinical manifestations and radiologic findings. We have conducted another investigation on the radio-pathologic findings of the disease in 224 patients and the severity of the disease is classified based on the description presented in this paper (Table 2). The clinical findings of the disease, along with radiologic and pathologic assessment of this large cohort of patients, will be presented soon.

Also, as an outcome measure, the researchers need a consistent classification of the response rate. This classification is crucial to evaluating the efficiency of each treatment modality, so we categorize the response to treatment based on the rate of improvement in the signs and symptoms as well as

*** Address for correspondence:**

Ahmad Kaviani, MD
Professor of Surgery,
Address: Imam Khomeini Hospital Complex, Tehran,
1419733141, Iran
Tel: +98 21 88871785
Fax: +98 21 88871698
Email: akaviani@archbreastcancer.com

Table 1. Classification of the signs and symptoms

| | |
|-----------------------|---|
| Inflammatory | Pain, Redness, Erythema, peau d'orange, skin thickening, axillary lymphadenopathy |
| Soft tissue* | Deep collections, tissue thickening, mass, skin dimpling, nipple retraction |
| Cutaneous Destructive | Thin red skin, superficial collection, Ulcer, fistula |
| Extramammary | Systemic lymphadenopathy, Arthralgia, Arthritis, Erythema nodosum, etc |

* This group needs to be studied by clinic-radiologic investigations. They can be considered mild when the collection is single with minimal inflammatory reaction around it, moderate when the collections are multiple in a single quadrant and severe when the collections can be seen in more than one quadrant.

Table 2. Grading of the severity of the disease

| Grade | Inflammatory | Soft tissue | Cutaneous destructive | Extramammary | Suggested Treatment |
|-------|------------------|--------------------|-----------------------|--------------|---|
| I | Mild | Mild | No | No | NSAIDs* |
| II | Mild to Moderate | Moderate to Severe | No | No | Percutaneous drainage ^o ANB ^g NSAIDs* |
| III | Sever | Moderate to Severe | Yes | No | Open drainage ANB ^g NSAIDs* + CS ^e + ISM ^h |
| IV | Any | Any | Any | Yes | Based on the protocols for systemic disease |

* Non-Steroidal Anti Inflammatory Drugs for three months

^o Should be done with large bore needles, preferably with the guide of ultrasonography

^g Widespectrum oral antibiotics with coverage on gram-positive microorganisms for 10-14 days

^e Corticosteroids can be used based on clinical impression with 50 mg prednisolone in a tapering dose, discontinue in 10 weeks. Can be continued in low dose (5-10mg/day) for a maximum of 3 months

^h Immunosuppressive medications can be used if only the disease is persistent in Grade III for 6 months

Table 3. Classification of “Response to Treatment” in breast-limited IGM

| | Initial Control of symptoms | No Recurrences* | Severity of the recurrences* |
|-------------------|-----------------------------|--------------------|------------------------------|
| Excellent Control | Complete ^o | 0 | - |
| Good Control | Complete ^o | 1-2 | Grade I-II |
| Fair Control | Partial ^g | 3-4 | Grade I-II |
| Poor Control | Fair ^e | Persistent disease | Grade III |

* During a 12-months follow up

^o Resolution of >90 percent of the signs and symptoms

^g Marked reduction in the signs and symptoms

^e Not a big resolution in signs and symptoms

the frequency of the recurrences (Table 3). It is clear that the clinical classifications will be authenticated if they are concordant with the imaging (ultrasonographic) findings.

Conflict of Interest

None.

References

- Erozgen F, Ersoy YE, Akaydin M, Memmi N, Celik AS, et al. Corticosteroid treatment and timing of surgery in idiopathic granulomatous mastitis confusing with breast carcinoma. *Breast Cancer Research and Treatment.* 2010;123(2): 447-52.
- Sripathi S, Ayachit A, Bala A, Kadavigere R, Kumar S. Idiopathic granulomatous mastitis: a diagnostic dilemma for the breast radiologist. *Insights into Imaging.* 2016;7(4):523-9.
- Barreto DS, Sedgwick EL, Nagi CS, Benveniste AP. Granulomatous mastitis: etiology, imaging, pathology, treatment, and clinical findings. *Breast Cancer Research and Treatment.* 2018;171(3):527-34.
- Martinez-Ramos D, Simon-Monterde L, Suelves-Piqueres C, Queralt-Martin R, Granel-Villach L, et al. Idiopathic granulomatous mastitis: A systematic review of 3060 patients. *The Breast Journal.* 2019;25(6):1245-50.
- Fazio RT, Shah SS, Sandhu NP, Glazebrook KN. Idiopathic granulomatous mastitis: imaging update and review. *Insights into Imaging.* 2016;7(4):531-9.
- Kessler E, Wolloch Y. Granulomatous mastitis: a lesion clinically simulating carcinoma. *American Journal of Clinical Pathology.* 1972;58(6):642-6.
- Zhou F, Liu L, Liu L, Yu L, Wang F, et al. Comparison of Conservative versus Surgical Treatment Protocols in Treating Idiopathic



- Granulomatous Mastitis: A Meta-Analysis. *Breast Care*. 2020;15(4):415-20.
8. Cetin K, Sıkar HE, Göret NE, Rona G, Barışık NÖ, et al. Comparison of topical, systemic, and combined therapy with steroids on idiopathic granulomatous mastitis: a prospective randomized study. *World Journal of Surgery*. 2019;43(11):2865-73.
 9. Kaviani A, Vasigh M, Omranipour R, Mahmoudzadeh H, Elahi A, et al. Idiopathic granulomatous mastitis: Looking for the most effective therapy with the least side effects according to the severity of the disease in 374 patients in Iran. *The Breast Journal*. 2019;25(4): 672-7.
 10. Kaviani A, Vasigh M, Zand S. Idiopathic Granulomatosis Mastitis, Time to a Paradigm Change in Treatment. *Iranian Journal of Breast Disease*, 2020, 13(2): 69-73.
 11. Azizi A, Prasath V, Canner J, Fattahi A, Sajjadi S, et al., editors. Idiopathic granulomatous mastitis: A closer look at demographic characteristics and factors associated with recurrence in 474 patients. *Annals Of Surgical Oncology*; 2019: Springer 233 Spring St, New York, Ny 10013 USA.
 12. Azizi A, Prasath V, Canner J, Gharib M, Sadat Fattahi A, et al. Idiopathic granulomatous mastitis: Management and predictors of recurrence in 474 patients. *The Breast Journal*. 2020;26(7):1358-1362.
 13. Kaviani A, Zand S, Karbaksh M, Ardalan FA. Synchronous idiopathic granulomatosis mastitis and breast cancer: a case report and review of literature. *Archives of Breast Cancer*. 2017;4(1):32-6.
 14. Kaviani A, Noveiry BB, Jamei K, Rabbani A. How to manage idiopathic granulomatous mastitis: suggestion of an algorithm. *The Breast Journal*. 2013;20(1):110-2.